Inside Information / Other news releases

Mauna Kea Technologies Announces Major Milestone for Cellvizio® in Pancreatic Cysts with CLIMB Study Selected for ASGE Presidential Plenary Session at DDW 2026

ASGE Presidential Plenary Session highlights the most impactful endoscopy research selected from thousands of submissions to Digestive Disease Week

Paris and Boston, March 11, 2026 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today proudly announces that the CLIMB study (Confocal Laser Endomicroscopy as an IMaging Biomarker, ClinicalTrials.gov ID: NCT03492151) will be presented at the ASGE (American Society for Gastrointestinal Endoscopy) Presidential Plenary Session on Sunday, May 3, 2026, one of the most prestigious sessions of the Digestive Disease Week (DDW) 2026 conference, to be held from May 2 to 5, 2026 in Chicago, Illinois.

This prospective multicenter study (over 500 patients across 14 U.S. centers) led by Dr. Somashekar (Som) Krishna, Professor of Medicine and Director of Advanced Endoscopy at The Ohio State University Wexner Medical Center, demonstrates the superiority of EUS-nCLE (Endoscopic Ultrasound-guided needle-based Confocal Laser Endomicroscopy using Cellvizio) for the multimodal diagnosis of pancreatic cystic lesions (PCLs), particularly IPMNs (intraductal papillary mucinous neoplasms), a common type of premalignant or malignant cyst. EUS-nCLE confirms unmatched diagnostic accuracy compared to standard methods (cyst fluid analysis: CEA, amylase, cytology, glucose), thanks to accurate cellular-level visualization which can improve patient management and outcomes.

This selection for the ASGE Presidential Plenary Session highlights the major clinical impact of Cellvizio and positions it as a key tool for the evolution of PCL management.

Dr. Krishna and his team illustrate academic excellence surrounding Cellvizio with 9 accepted works (6 lectures, 3 posters) covering:

• Precise real-time diagnosis (e.g., serous cystadenomas) and reduction of inappropriate surgeries via multimodal approaches;
• Artificial intelligence for automated detection and classification of cysts from EUS-nCLE videos;
• Medico-economic analyses favoring EUS-RFA (Endoscopic Ultrasound-guided Radiofrequency Ablation) vs. surgical resection.

Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies, commented: "The selection of the CLIMB study for the ASGE Presidential Plenary Session at DDW 2026 represents a major recognition for Cellvizio and the growing body of clinical evidence supporting its role in the management of pancreatic cysts. The study highlights the unparalleled accuracy as well as multicenter robustness and reproducibility of nCLE in this challenging indication. Since DDW 2025, we have seen strong and increasing demand for Cellvizio in pancreatic cyst evaluation. Through my numerous interactions with physicians across the United States, it is clear that a significant number of interventional endoscopists now view Cellvizio as an essential tool for characterization and risk-stratification of pancreatic cystic lesions. We believe that the visibility of the CLIMB study at DDW 2026 will further accelerate adoption, and we look forward to supporting a growing number of centers integrating Cellvizio into their clinical practice."

***

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.

Mauna Kea Technologies
investors@maunakeatech.com

NewCap - Investor Relations
Thomas Grojean
+33 (0)1 44 71 94 94
maunakea@newcap.eu

Disclaimer

The present press release, together with the safeguard plan, contains forward-looking statements relating to Mauna Kea Technologies, its business and the course of the safeguard proceedings opened for the benefit of the Company. All statements other than statements of historical fact included in this press release and in the safeguard plan, including, without limitation, those regarding Mauna Kea Technologies’ financial position, business, strategies, plans and management objectives for future operations, are forward-looking statements. Mauna Kea Technologies believes that such forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the projections set forth in such forward-looking statements will be achieved, as they are subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies’ 2024 Annual Report filed with the Autorité des marchés financiers (AMF) on April 30, 2025, available on the Company’s website (www.maunakeatech.fr), as well as risks relating to changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release and in the safeguard plan are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material as of the date hereof. The occurrence of all or part of such risks could cause Mauna Kea Technologies’ actual results, financial condition, performance or achievements to differ materially from those expressed in such forward-looking statements. This press release, the safeguard plan and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, Mauna Kea Technologies shares in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Likewise, they do not constitute and should not be treated as investment advice. They do not take into account the investment objectives, financial situation or particular needs of any recipient. No representation or warranty, express or implied, is made as to the accuracy, completeness or reliability of the information contained in these documents. Readers should not regard them as a substitute for the exercise of their own judgment. All opinions expressed in these documents are subject to change without notice. This document does not constitute an offer to sell or the solicitation of an order to buy or subscribe for the Company’s securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration of the relevant securities or any other qualification under the securities regulations of such country or jurisdiction.

The distribution of this document may be subject to specific regulations in certain countries. Persons who come into possession of this document should inform themselves about, and comply with, any applicable local restrictions.